Scarica l'app Stockscreener
2.85
0.00%
0.00
Dopo l'orario di chiusura:
2.85
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures - MSN
HC Wainwright Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q3 EPS Forecast for Jasper Therapeutics Reduced by Analyst - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
UBS Group Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price - Defense World
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75 - Defense World
UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating - MarketScreener
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $12 to $25 - 富途牛牛
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline - TipRanks
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays, Competitive Pressures - AInvest
Jasper Therapeutics' Promising Clinical Data and Strategic Focus Earn Buy Rating - AInvest
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks By Investing.com - Investing.com India
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks - Investing.com
Jasper Therapeutics Reports Promising Q2 2025 Results - MSN
BTIG reiterates Buy rating on Jasper Therapeutics stock with $20 price target - Investing.com Canada
JMP reiterates Market Outperform rating on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper Reports Wider Loss in Fiscal Q2 - AOL.com
Jasper Therapeutics shares fall 4.65% after-hours following Q2 2025 earnings report. - AInvest
Jasper Reports Wider Loss in Fiscal Q2 - The Motley Fool
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33) - TipRanks
Assessing Jasper Therapeutics' Earnings Miss and Clinical Pipeline Momentum in a High-Risk, High-Reward Biotech Play - AInvest
Jasper Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jasper Therapeutics shares rise 3.51% intraday after Metagenomi reported positive business updates and financial results. - AInvest
Jasper Therapeutics under investigation for alleged securities fraud. - AInvest
Jasper Therapeutics shares rise 5.70% intraday after Metagenomi appoints Laurence Reid, PhD to its Board of Directors. - AInvest
Jasper Therapeutics Inc (JSPR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
How does the Q2 2025 earnings report affect JSPR's stock price? - AInvest
Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Tuesday - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at EF Hutton Acquisition Co. I - 富途牛牛
Jasper Therapeutics WRT JSPRW Q2 2025 Earnings Preview Downside Expected Amid Technical Integration Hurdles - AInvest
Jasper Therapeutics JSPR 2025Q2 Earnings Preview Downside Ahead on Technical Challenges and Report Compilation Errors - AInvest
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Jasper Therapeutics Inc expected to post a loss of $1.33 a shareEarnings Preview - TradingView
Jasper Therapeutics shares fall 3.02% intraday after Pomerantz Law Firm investigates claims of securities fraud. - AInvest
What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - Jammu Links News
What are the latest earnings results for Jasper Therapeutics Inc.Smart Portfolio Planner With Proven Results - Jammu Links News
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - Jammu Links News
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - Jammu Links News
What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - Jammu Links News
What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - Jammu Links News
What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - Jammu Links News
How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com
Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - Jammu Links News
What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - Jammu Links News
What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - Jammu Links News
Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Why is Jasper Therapeutics Inc. Equity Warrant stock attracting strong analyst attentionMaximize portfolio value with smart investment plans - Jammu Links News
How does Jasper Therapeutics Inc. compare to its industry peersFree Stock Forecasts For 2025 - jammulinksnews.com
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):